2,3,3a,4,5,6-Hexahydro-1H-1-aza-phenalene | 42025-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,3,3a,4,5,6-Hexahydro-1H-1-aza-phenalene
• 英文别名: 2-Azatricyclo[7.3.1.0,5,13]trideca-1(12),9(13),10-triene；2,3,3a,4,5,6-hexahydro-1H-benzo[de]quinoline
• CAS: 42025-44-5
• 化学式: C₁₂H₁₅N
• mdl: MFCD20673416
• 分子量: 173.258
• InChiKey: MOKQEVNZBIAXIF-UHFFFAOYSA-N

物化性质

• 沸点：
  287.4±30.0 °C(Predicted)
• 密度：
  1.056±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Novel derivatives and analogues of galanthamin
  申请人：——

  公开号：US20030199493A1

  公开（公告）日：2003-10-23

  New compounds of general formula I 1

  通式I1的新化合物
• Process for producing tricyclic fused heterocyclic derivative
  申请人：——

  公开号：US20030191150A1

  公开（公告）日：2003-10-09

  A process for easily and industrially advantageously producing both a tricyclic fused heterocyclic derivative having acetylcholinesterase inhibitory activity and an intermediate for the derivative. The process for producing the target compounds comprises the following reaction. 1

  一种用于方便地和工业上有利地生产既具有乙酰胆碱酯酶抑制活性的三环融合杂环衍生物，又具有该衍生物的中间体的方法。用于生产目标化合物的过程包括以下反应。1
• Preventives and remedies for central nervous system diseases
  申请人：——

  公开号：US20030207863A1

  公开（公告）日：2003-11-06

  A prophylactic or therapeutic agent for central nervous system diseases based on amyloid &bgr;40 secretion inhibitory activity of a compound having urotensin II receptor antagonistic activity or a salt thereof.

  一种预防或治疗中枢神经系统疾病的药剂，基于一种具有尿泰松II受体拮抗活性或其盐的化合物对淀粉样蛋白β40分泌抑制活性。
• Agents and crystals for improving excretory potency of urinary bladder
  申请人：——

  公开号：US20020177593A1

  公开（公告）日：2002-11-28

  Agents for improving potentcy of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholine esterase and an action to improve the excretory potency of urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.

  改善膀胱功能的药剂，包括一种非卡巴酯类胺化合物，具有乙酰胆碱酯酶抑制作用。特别地，提供了一种三环、紧凑、杂环衍生物的晶体，具有优异的抑制乙酰胆碱酯酶作用和改善膀胱排泄功能的作用。例如，揭示了8-[3-[1-[(3-氟苯基)-甲基]-4-哌啶基]-1-氧代丙基]-1,2,5,6-四氢-4H-吡咯烷[3,2,1-ij]-喹啉-4-酮或其盐和含有它们的药物组合物。
• Agents for improving excretory potency of urinary bladder
  申请人：——

  公开号：US20040116457A1

  公开（公告）日：2004-06-17

  Agents for improving excretory potency of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action.

  改善排泄能力的尿道代理，包括一种非卡巴酯型胺类化合物，具有乙酰胆碱酯酶抑制作用。